[go: up one dir, main page]

LU91620I2 - Rituximab et ses dérivés pharmaceutiquement acceptables - MABTHERA® - Google Patents

Rituximab et ses dérivés pharmaceutiquement acceptables - MABTHERA®

Info

Publication number
LU91620I2
LU91620I2 LU91620C LU91620C LU91620I2 LU 91620 I2 LU91620 I2 LU 91620I2 LU 91620 C LU91620 C LU 91620C LU 91620 C LU91620 C LU 91620C LU 91620 I2 LU91620 I2 LU 91620I2
Authority
LU
Luxembourg
Prior art keywords
mabthera
rituximab
pharmaceutically acceptable
acceptable derivatives
antibody
Prior art date
Application number
LU91620C
Other languages
English (en)
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25526490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91620(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP94901444A external-priority patent/EP0669836B1/fr
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of LU91620I2 publication Critical patent/LU91620I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91620C 1992-11-13 2009-11-11 Rituximab et ses dérivés pharmaceutiquement acceptables - MABTHERA® LU91620I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97889192A 1992-11-13 1992-11-13
US08/149,099 US5736137A (en) 1992-11-13 1993-11-03 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP94901444A EP0669836B1 (fr) 1992-11-13 1993-11-12 Application therapeutique d'anticorps chimeriques et radio-marques contre l'antigene a differentiation restreinte des lymphocytes b humains pour le traitement du lymphome des cellules b
EP96200772A EP0752248B1 (fr) 1992-11-13 1993-11-12 Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à differentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B
EP99123967A EP1005870B1 (fr) 1992-11-13 1993-11-12 Application thérapeutique d'anticorps chimériques et radio-marqués contre l'antigène à différentiation restreinte des lymphocytes B humains pour le traitement du lymphome des cellules B

Publications (1)

Publication Number Publication Date
LU91620I2 true LU91620I2 (fr) 2010-01-11

Family

ID=25526490

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91620C LU91620I2 (fr) 1992-11-13 2009-11-11 Rituximab et ses dérivés pharmaceutiquement acceptables - MABTHERA®

Country Status (24)

Country Link
US (2) US5736137A (fr)
EP (1) EP2000149B1 (fr)
KR (1) KR100365632B1 (fr)
CN (5) CN1607006B (fr)
AT (2) ATE421335T1 (fr)
BR (1) BR1100622A (fr)
CA (1) CA2626445A1 (fr)
DE (3) DE69334285D1 (fr)
DK (2) DK1005870T3 (fr)
ES (2) ES2326144T3 (fr)
FR (1) FR04C0018I2 (fr)
GE (3) GEP20074162B (fr)
HK (3) HK1109634A1 (fr)
HU (1) HU219264B (fr)
IL (1) IL107591A (fr)
LU (1) LU91620I2 (fr)
MY (1) MY111196A (fr)
NL (1) NL300424I1 (fr)
PL (1) PL175557B1 (fr)
PT (2) PT1005870E (fr)
SG (1) SG45294A1 (fr)
TW (1) TW376320B (fr)
UA (1) UA27946C2 (fr)
ZA (1) ZA938466B (fr)

Families Citing this family (723)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
NZ258392A (en) * 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US8771694B2 (en) * 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
ATE306930T1 (de) * 1994-08-12 2005-11-15 Immunomedics Inc Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US20030180290A1 (en) * 1995-06-07 2003-09-25 Idec Pharmaceuticals Corporation Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
US6373497B1 (en) * 1999-05-14 2002-04-16 Zight Corporation Time sequential lookup table arrangement for a display
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6699672B1 (en) 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6562950B2 (en) * 1997-09-02 2003-05-13 Insight Strategy & Marketing Ltd. Heparanase activity neutralizing anti-heparanase monoclonal antibody
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) * 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
HU228180B1 (hu) 1998-08-11 2013-01-28 Biogen Idec Inc Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
DK1616572T3 (da) 1998-11-09 2010-12-06 Biogen Idec Inc Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi
KR20010099788A (ko) * 1998-11-09 2001-11-09 케네쓰 제이. 울코트 Ｂｍｔ 또는 ｐｂｓｃ 이식을 받은 환자의 키메라항-ｃｄ２０ 항체 치료법
WO2000029431A1 (fr) * 1998-11-17 2000-05-25 Tanox, Inc. Reticulation de molecules bispecifiques du motif d'activation a base de tyrosine des immunorecepteurs avec le motif d'inhibition a base de tyrosine des immunorecepteurs, dans un but therapeutique
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
JP2002544174A (ja) * 1999-05-07 2002-12-24 ジェネンテック・インコーポレーテッド Ｂ細胞表面マーカーに結合するアンタゴニストを用いた自己免疫疾患の治療
EP1645290A1 (fr) 1999-05-07 2006-04-12 Genentech, Inc. Traitement de maladies auto-immunes au moyen d'antagonistes se liant aux marqueurs de surface de lymphocytes B
ES2331644T3 (es) * 1999-06-09 2010-01-12 Immunomedics, Inc. Inmunoterapia de trastornos autoinmunes usando anticuerpos cuya diana son celulas b.
ITMI991299A1 (it) * 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1189634B1 (fr) * 1999-06-25 2007-02-28 Genentech, Inc. Traitement du cancer de la prostate a l'aide des anticorps anti-erbb2
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
BR0013201A (pt) * 1999-07-12 2002-04-30 Genentech Inc Método de bloqueio de uma resposta imunológica a um antigeno externo em mamìferos através da utilização de um antagonista que se liga ao cd20, método de tratamento de mamìferos, método de tratamento de uma doença de enxerto contra hospedeiro ou hospedeiro contra enxerto em mamìferos, método de insensibilização de mamìferos que aguardam transplante e artigo industrializado
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6451284B1 (en) * 1999-08-11 2002-09-17 Idec Pharmaceuticals Corporation Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2002004021A1 (fr) * 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN1407901A (zh) * 1999-11-08 2003-04-02 Idec药物公司 使用抗cd40l抗体并联合抗cd20抗体和/或化疗剂和放疗治疗b细胞恶性瘤
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20030185796A1 (en) * 2000-03-24 2003-10-02 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
BR0109705A (pt) * 2000-03-31 2005-01-11 Idec Pharma Corp Uso combinado de anticorpos ou antagonistas anti-citocina e anticd20 para o tratamento de linfoma de célula b
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
EP2264072A1 (fr) 2000-04-13 2010-12-22 The Rockefeller University Amélioration de la réponse cytotoxique à médiation d'anticorps.
WO2001080884A1 (fr) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Administration intrathecale de rituximab pour le traitement des lymphomes du systeme nerveux central
EP1280923A2 (fr) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, un nouveau membre dans la famille de la trypsine humaine et son utilisation
KR20080038458A (ko) 2000-05-19 2008-05-06 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인반응의 가능성을 개선시키기 위한 유전자 검출 분석
CA2411102A1 (fr) * 2000-06-20 2001-12-27 Idec Pharmaceutical Corporation Traitement de maladies associees aux cellules beta telles que les maladies auto-immunes a caractere malin par combinaison anticorps anti-cd20 froid/anticorps anti-cd22 radiomarque
JP2003535908A (ja) * 2000-06-22 2003-12-02 アイデック ファーマスーティカルズ コーポレイション 二重特異性融合タンパク及び標的細胞を殺傷するエフェクター細胞を増強するための使用方法
US20060034830A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
US20060029604A1 (en) * 2000-06-28 2006-02-09 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
US20060034828A1 (en) * 2000-06-28 2006-02-16 Gerngross Tillman U Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
US20060024304A1 (en) * 2000-06-28 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
US20020128448A1 (en) * 2000-10-20 2002-09-12 Idec Pharmaceuticals Corporation Variant IgG3 Rituxan and therapeutic use thereof
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PL364623A1 (en) * 2001-01-17 2004-12-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
AU2008200400B2 (en) * 2001-01-17 2012-06-07 Aptevo Research And Development Llc Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (fr) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Anticorps immunoregulateurs et ses utilisations
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
CN1494433A (zh) 2001-01-31 2004-05-05 IDECҩ�﹫˾ Cd23拮抗剂用于治疗肿瘤性疾病的用途
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
EP1383800A4 (fr) * 2001-04-02 2004-09-22 Idec Pharma Corp Anticorps recombinants co-exprimes avec gntiii
AU2002250352C1 (en) 2001-04-02 2009-04-30 Genentech, Inc. Combination therapy
WO2002080987A1 (fr) * 2001-04-09 2002-10-17 Progenics Pharmaceuticals, Inc. Immunotoxines anti-cd19
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
AU2002316230A1 (en) * 2001-06-13 2002-12-23 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
KR20040054669A (ko) * 2001-08-03 2004-06-25 글리카트 바이오테크놀로지 아게 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체
PL377119A1 (pl) * 2001-08-03 2006-01-23 Genentech, Inc. Peptydy TACIs i BR3 i ich zastosowanie
US7255858B2 (en) * 2001-08-10 2007-08-14 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
US7214428B2 (en) * 2001-09-17 2007-05-08 Invitrogen Corporation Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
US7205048B2 (en) 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
US6955855B2 (en) * 2001-09-17 2005-10-18 Biocrystal, Ltd. Nanocrystals
ATE443259T1 (de) 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
EP2305312B1 (fr) 2001-10-10 2015-03-04 ratiopharm GmbH Remodelage et glycoconjugation de l'hormone folliculo-stimulante (FSH)
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
DE02782887T1 (de) * 2001-10-19 2005-01-13 Centre Hospitalier Regional et Universitair de Tours Methoden und kompositionen, antikörper behandlung zu bewerten
US20030157108A1 (en) * 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
EP2022799A2 (fr) 2001-11-16 2009-02-11 Biogen Idec Inc. Expression polycistronique d'anti-corps
US20060024292A1 (en) * 2001-12-27 2006-02-02 Gerngross Tillman U Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
DE60325334D1 (de) 2002-02-05 2009-01-29 Genentech Inc Proteinaufreinigung
US20040005298A1 (en) 2002-02-08 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune responsiveness in patients with immunological defects
CN101914158A (zh) * 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20090042291A1 (en) * 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
ATE477276T1 (de) * 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
HUE025101T2 (en) 2002-04-26 2016-02-29 Genentech Inc Purification of proteins other than affinity purification
MXPA05000940A (es) * 2002-07-25 2005-05-16 Genentech Inc Anticuerpos taci y su uso.
US8044180B2 (en) * 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
DK1553975T3 (da) 2002-09-27 2012-05-07 Xencor Inc Optimerede Fc-varianter og fremgangsmåder til generering heraf.
WO2004035607A2 (fr) * 2002-10-17 2004-04-29 Genmab A/S Anticorps monoclonaux humains anti-cd20
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
CA2506320A1 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
SE0203731D0 (sv) * 2002-12-13 2002-12-13 Mitra Medical Technology Ab Reagent
EP2301966A1 (fr) * 2002-12-16 2011-03-30 Genentech, Inc. Variantes de l'immunoglobuline et leurs utilisations
EP2368578A1 (fr) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification et ingénierie d'anticorps avec régions FC de variante et procédés d'utilisation associés
US7960512B2 (en) * 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP4177123B2 (ja) * 2003-01-10 2008-11-05 富士通株式会社 配線図形検証方法、プログラム及び装置
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
AU2004207538A1 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using IGSF9 and LIV-1
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
AU2004229376B2 (en) 2003-04-09 2007-12-13 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN1802388B (zh) * 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法
BRPI0411276A (pt) 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
WO2004108065A2 (fr) * 2003-06-09 2004-12-16 Insight Biopharmaceuticals Ltd. Activite d'heparanase neutralisant un anticorps monoclonal anti-heparanase et d'autres anticorps anti-heparanase
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
ES2786568T3 (es) 2003-07-28 2020-10-13 Genentech Inc Reducción de la lixiviación de la proteína A durante la cromatografía de afinidad con proteína A
ZA200600798B (en) * 2003-07-29 2007-06-27 Genentech Inc Assay for human anti CD20 antibodies and uses therefor
WO2005023302A2 (fr) * 2003-08-29 2005-03-17 Genentech, Inc. Traitement de troubles oculaires
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
BRPI0416243A (pt) * 2003-11-05 2007-01-09 Palingen Inc método de tratamento de um paciente humano que sofre de uma condição que inclui uma hiper-proliferação de células b; formulação farmacêutica para injeção parenteral; kit para o tratamento de um paciente que sofre de uma condição que inclui uma hiper-proliferação de células b; e método para purgar a medula óssea de um paciente que sofre de cáncer linfóide de células b malignas antes do reimplante da medula óssea no paciente após a terapia mieloablativa
ME02332B (fr) * 2003-11-05 2016-06-30 Roche Glycart Ag Molécules de liaison d'antigène avec affinité de liaison de récepteur Fc améliorée et fonction d'effecteur
CA2545603A1 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
BRPI0417105A (pt) * 2003-12-19 2007-02-06 Genentech Inc métodos de tratamento de doenças autoimunológicas em pacientes
BRPI0417108A (pt) * 2003-12-19 2007-02-06 Genentech Inc métodos de tratamento de rejeições de transplantes em pacientes
FR2867982B1 (fr) * 2004-03-26 2007-07-20 Jean Marie Andrieu Procede pour amplifier l'activite de vaccins therapeutiques
ZA200608572B (en) * 2004-04-16 2008-06-25 Genentech Inc Assay for antibodies
WO2005113003A2 (fr) * 2004-04-16 2005-12-01 Genentech, Inc. Methode permettant d'augmenter l'appauvrissement des lymphocytes b
WO2005115453A2 (fr) * 2004-04-16 2005-12-08 Genentech, Inc. Traitement de troubles
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
BRPI0510224A (pt) * 2004-05-05 2007-10-23 Genentech Inc métodos de prevenção de doença autoimunológica e artigo industrializado
ES2390278T3 (es) 2004-05-20 2012-11-08 Zymogenetics, Inc. Procedimientos de tratamiento del cáncer usando tratamiento con IL-21 y anticuerpos monoclonales
PA8635501A1 (es) * 2004-06-04 2006-06-02 Genentech Inc Uso de un anticuerpo para el tratamiento del lupus
CN102512675A (zh) * 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
US9109255B2 (en) * 2004-06-18 2015-08-18 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining responsiveness to antibody therapy
DK2471813T3 (en) 2004-07-15 2015-03-02 Xencor Inc Optimized Fc variants
US20060062787A1 (en) * 2004-07-22 2006-03-23 Genentech, Inc. Method for treating Sjogren's syndrome
EP1771476B1 (fr) 2004-07-23 2014-12-10 Genentech, Inc. Cristallisation d'anticorps anti-vegf
KR100864549B1 (ko) 2004-08-04 2008-10-20 어플라이드 몰리큘라 에볼류션, 인코포레이티드 변이체 ｆｃ 영역
JP2008510852A (ja) * 2004-08-17 2008-04-10 インヴィトロジェン コーポレーション 高発光性コロイド粒子の合成
CN101052654A (zh) * 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
US7662926B2 (en) * 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
WO2006028956A2 (fr) * 2004-09-02 2006-03-16 Genentech, Inc. Anticorps anti-recepteur fcgammariib et correspondantes
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US20090175854A1 (en) * 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
BRPI0515615A (pt) * 2004-09-08 2008-07-29 Genentech Inc métodos para tratar células cancerosas e doença imune relacionada
CN101087807A (zh) * 2004-10-05 2007-12-12 健泰科生物技术公司 治疗血管炎的方法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2305775A3 (fr) 2004-10-29 2011-06-08 Molecular Probes, Inc. Nanocristaux fluorescents fonctionnalisés et procédés pour leur préparation et utilisation
CA2587766A1 (fr) * 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2845865A1 (fr) 2004-11-12 2015-03-11 Xencor Inc. Variantes Fc avec liaison altérée en FcRn
GB2420976B (en) * 2004-11-19 2006-12-20 Zvi Finkelstein Therapeutic implant
JP2008524241A (ja) * 2004-12-17 2008-07-10 ジェネンテック・インコーポレーテッド 従来の治療の効果がなかった患者の自己免疫性疾患の血管新生阻害治療
EP1674479A1 (fr) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation des récepteurs Fc gamma pour optimiser l'immunothérapie
EP2290088A1 (fr) 2004-12-22 2011-03-02 Genentech, Inc. Méthode de production de protéines multi-membranaires
DE602004021404D1 (de) 2004-12-23 2009-07-16 Gpc Biotech Ag Quadratsäurederivate mit antiproliferativer Wirkung
US7955806B2 (en) * 2004-12-23 2011-06-07 Hoffmann—La Roche Inc. Detection of a therapeutic antibody in an experimental animal
EP2311880A3 (fr) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Molécules à crypto-liaison
CA2590163A1 (fr) * 2005-01-13 2006-07-20 Genentech, Inc. Procede de traitement
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
EP3479844B1 (fr) * 2005-04-15 2023-11-22 MacroGenics, Inc. Dianticorps covalents et leurs utilisations
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1874350A2 (fr) * 2005-04-22 2008-01-09 Genentech, Inc. Méthode pour traiter la démence ou la maladie d'alzheimer avec un anticorps cd20
US8034902B2 (en) * 2005-05-04 2011-10-11 Quark Pharmaceuticals, Inc. Recombinant antibodies against CD55 and CD59 and uses thereof
MX2007013924A (es) * 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
KR20080046135A (ko) * 2005-05-20 2008-05-26 제넨테크, 인크. 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리
BRPI0610203A2 (pt) * 2005-05-24 2010-06-01 Avestha Gengraine Tech Pvt Ltd processo de preparação in vivo de anti-corpo monoclonal anti-cd 20 biologicamente ativo e composição farmacêutica
CN101495509B (zh) 2005-07-08 2015-04-22 比奥根艾迪克Ma公司 Sp35抗体及其用途
KR101251157B1 (ko) 2005-07-25 2013-04-10 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 Ｃｄ37-특이적 결합 분자 및 ｃｄ20-특이적 결합 분자를사용한 ｂ-세포 감소
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
EP2415483A1 (fr) 2005-07-25 2012-02-08 Emergent Product Development Seattle, LLC Utilisation de dose unique de molécules de liaison spécifique au CD20
LT2573114T (lt) 2005-08-10 2016-10-10 Macrogenics, Inc. Atpažinimas ir konstravimas antikūnų su variantinėmis fc sritimis ir jų panaudojimo būdai
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2618482C (fr) 2005-08-19 2014-10-07 Abbott Laboratories Immunoglobuline a deux domaines variables et utilisations de celle-ci
EP2500356A3 (fr) 2005-08-19 2012-10-24 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
WO2007028144A2 (fr) * 2005-09-02 2007-03-08 Glycofi, Inc Immunoglobulines comprenant principalement une glycoforme glcnacman3glcnac2
EP1931709B1 (fr) 2005-10-03 2016-12-07 Xencor, Inc. Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées
US20070161089A1 (en) * 2005-11-08 2007-07-12 Genentech, Inc. Method of Producing Pan-Specific Antibodies
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
EP1952150B1 (fr) * 2005-11-23 2016-12-14 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007102200A1 (fr) 2006-03-07 2007-09-13 Osaka University Anticorps monoclonal anti-cd20
CA2644903A1 (fr) * 2006-03-10 2007-09-20 Macrogenics, Inc. Identification et modification genetique d'anticorps avec des chaines lourdes de variants et leurs procedes d'utilisation
RU2008141912A (ru) 2006-03-23 2010-04-27 Новартис АГ (CH) Противоопухолевые лекарства на основе антител к клеточным антигенам
CA2650730A1 (fr) 2006-04-27 2007-11-08 Pikamab, Inc. Procedes et compositions pour la therapie par anticorps
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
US7727525B2 (en) * 2006-05-11 2010-06-01 City Of Hope Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
ES2489646T3 (es) * 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
EP2041178A2 (fr) * 2006-06-12 2009-04-01 Trubion Pharmaceuticals, Inc. Proteines de liaison monocatenaires polyvalentes dotees d'une fonction d'effecteur
CA2656224C (fr) * 2006-06-26 2018-01-09 Macrogenics, Inc. Association d'anticorps anti-fc.gamma.riib et d'anticorps anti-cd20, et methodes d'utilisation
WO2008019199A2 (fr) * 2006-06-26 2008-02-14 Macrogenics, Inc. ANTICORPS SPÉCIFIQUES DU FCγRIIB ET LEURS PROCÉDÉS D'UTILISATION
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8372399B2 (en) * 2006-08-31 2013-02-12 Cardiac Pacemakers, Inc. Bispecific antibodies and agents to enhance stem cell homing
US8636995B2 (en) * 2006-08-31 2014-01-28 Cardiac Pacemakers, Inc. Methods and devices to regulate stem cell homing
US20080058922A1 (en) * 2006-08-31 2008-03-06 Cardiac Pacemakers, Inc. Methods and devices employing vap-1 inhibitors
US20080112961A1 (en) * 2006-10-09 2008-05-15 Macrogenics, Inc. Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
PT2436696T (pt) 2007-01-05 2017-08-21 Univ Zuerich Anticorpo anti-beta-amiloide e usos do mesmo
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
ES2374330T3 (es) 2007-01-22 2012-02-15 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos.
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
IN2009DN05758A (fr) * 2007-03-12 2015-07-24 Esbatech Ag
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2008122039A2 (fr) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molécules d'anticorps hybrides médiées par la sélénocystéine
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP1995309A1 (fr) * 2007-05-21 2008-11-26 Vivalis Production de protéine recombinante dans des cellules aviaires EBx
EP2019101A1 (fr) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one utile en tant que Inhibiteur de kinase
PT2164961E (pt) * 2007-06-25 2015-04-08 Esbatech Alcon Biomed Res Unit Manipulação baseada em sequências e otimização de anticorpos de cadeia única
HUE027507T2 (en) * 2007-06-25 2016-10-28 Esbatech Alcon Biomed Res Unit Procedures for Modifying Antibodies and Modified Antibodies with Improved Functional Properties
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
DK3597659T5 (da) 2007-07-09 2024-09-02 Genentech Inc Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
EP2178916B1 (fr) * 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Anticorps humains contre le cd20 humain et leur procede d'utilisation
AU2008295140A1 (en) * 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Combination therapy with type I and type II anti-CD20 antibodies
EP2205249B1 (fr) 2007-09-28 2018-11-07 Intrexon Corporation Constructions et bioréacteurs de commutation de gène théapeutique destinés à l'expression de molécules biothérapeutiques, et utilisation de ceux-ci
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
EP2233149B1 (fr) 2007-10-16 2016-02-10 ZymoGenetics, Inc. Combinaison de l'activateur transmembranaire et modulateur calcique et interacteur du ligand de cyclophiline (TACI) et d'un agent anti-CD20 pour le traitement des maladies auto-immunes
WO2009052617A1 (fr) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Régime de traitement pour des troubles prolifératifs
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
KR20150008503A (ko) 2007-10-30 2015-01-22 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
US8795667B2 (en) * 2007-12-19 2014-08-05 Macrogenics, Inc. Compositions for the prevention and treatment of smallpox
JP2011507897A (ja) * 2007-12-21 2011-03-10 ジェネンテック， インコーポレイテッド リツキシマブ抵抗性関節リウマチ患者の治療
CN105418762B (zh) 2007-12-26 2019-11-05 Xencor公司 与FcRn结合改变的Fc变体
EP2077281A1 (fr) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anticorps anti-CD20 ou fragments correspondants pour le traitement de syndrome de fatigue chronique
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2085095B1 (fr) 2008-01-17 2012-03-07 Philogen S.p.A. Combinaison de protéine de fusion anticorps de fibronectine anti-EDb-IL-2, et molécule se liant aux lymphocytes B, progéniteurs de lymphocytes B et/ou leur contrepartie cancéreuse
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
US8883155B2 (en) * 2008-01-28 2014-11-11 The Regents Of The University Of California Methods for treating hematopoietic malignancies
CN107198772A (zh) * 2008-03-25 2017-09-26 罗氏格黎卡特股份公司 Ii型抗cd20抗体与环磷酰胺、长春新碱和多柔比星联合治疗非霍奇金淋巴瘤的应用
WO2009123894A2 (fr) 2008-04-02 2009-10-08 Macrogenics, Inc. Anticorps spécifiques de her2/neu et procédés d’utilisation de ceux-ci
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
EP2112152A1 (fr) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones comme inhibiteurs Plk
EP2112150B1 (fr) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Inhibiteurs Raf améliorés
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
US20090269339A1 (en) * 2008-04-29 2009-10-29 Genentech, Inc. Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
TW201006485A (en) * 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726845C (fr) * 2008-06-04 2017-09-26 Macrogenics, Inc. Anticorps a liaison alteree a fcrn et leurs procedes d'utilisation
WO2009151514A1 (fr) * 2008-06-11 2009-12-17 Millipore Corporation Bioréacteur à cuve agitée
DK3241843T3 (da) 2008-06-25 2021-09-06 Novartis Ag Opløselighedsoptimering af immunbindere
WO2010003057A2 (fr) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Traitement du cancer
KR101054362B1 (ko) 2008-07-03 2011-08-05 재단법인 목암생명공학연구소 재조합 단백질의 푸코스 함량을 감소시키는 방법
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8058406B2 (en) 2008-07-09 2011-11-15 Biogen Idec Ma Inc. Composition comprising antibodies to LINGO or fragments thereof
KR101030978B1 (ko) * 2008-07-10 2011-04-28 (주) 에이프로젠 동물세포용 재조합 발현벡터
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US20100021460A1 (en) * 2008-07-15 2010-01-28 Genentech, Inc. Methods of Treating Autoimmune Diseases Using CD4 Antibodies
EA201100228A1 (ru) * 2008-07-21 2011-08-30 Иммьюномедикс, Инк. Структурные варианты антител для улучшения терапевтических характеристик
US8900851B2 (en) * 2008-07-22 2014-12-02 The Research Foundation For The State University Of New York Multi-well platform
RS59232B1 (sr) 2008-08-14 2019-10-31 Genentech Inc Postupci za uklanjanje zagađivača koristeći hromatografiju membrane razmene jona sa razmeštanjem autohtonih proteina
CA2734275A1 (fr) 2008-09-10 2010-03-18 Genentech, Inc. Compositions et procedes permettant d'eviter la degradation oxydative des proteines
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
AP2011005739A0 (en) * 2008-10-28 2011-06-30 Avesthagen Ltd An expression vector and processes thereof.
US20100233079A1 (en) * 2008-12-04 2010-09-16 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
GB2466025A (en) 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
WO2010068722A1 (fr) 2008-12-12 2010-06-17 Medimmune, Llc Cristaux et structure d'un variant de fc d'igg humain avec liaison augmentée à fcrn
JP2012511929A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン 攪拌タンク反応器及び方法
SG171764A1 (en) * 2008-12-16 2011-07-28 Millipore Corp Purification of proteins
PL2370466T3 (pl) 2008-12-19 2015-12-31 Biogen Int Neuroscience Gmbh Ludzkie autoprzeciwciała anty-alfa-synukleina
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
AU2009334498A1 (en) 2008-12-31 2011-07-21 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
JP5828151B6 (ja) 2009-01-06 2018-09-19 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル アテローム性動脈硬化の処置のためのｂ細胞枯渇剤
EP2400992B1 (fr) 2009-02-27 2015-07-22 Genentech, Inc. Procédés et compositions pour le marquage des protéines
JP5836807B2 (ja) 2009-03-05 2015-12-24 アッヴィ・インコーポレイテッド Ｉｌ−１７結合タンパク質
MX341884B (es) 2009-03-10 2016-09-07 Biogen Ma Inc Anticuerpos anti-antigeno de maduracion de celulas b (bcma).
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
EP2233500A1 (fr) 2009-03-20 2010-09-29 LFB Biotechnologies Variantes Fc optimisées
RU2542394C2 (ru) 2009-03-24 2015-02-20 ТЕВА БИОФАРМАСЬЮТИКАЛЗ ЮЭсЭй, ИНК. Гуманизированные антитела против light и их применение
US20100247484A1 (en) 2009-03-31 2010-09-30 Heinrich Barchet Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
EP2435476A4 (fr) * 2009-05-27 2013-04-17 Synageva Biopharma Corp Anticorps d'origine aviaire
EP2443234B1 (fr) 2009-06-15 2018-08-15 Icon Genetics GmbH Plants de nicotinia benthamiana à activité xylosyltransférase déficiente
EP2711018A1 (fr) 2009-06-22 2014-03-26 MedImmune, LLC Régions Fc modifiées pour conjugaison spécifique d'un site
WO2011000543A1 (fr) * 2009-06-30 2011-01-06 Philochem Ag Banque de présentation d’anticorps murin
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
MX2012001742A (es) 2009-08-11 2012-03-21 Genentech Inc Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
NZ597325A (en) 2009-08-14 2014-03-28 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
US9428548B2 (en) 2009-09-01 2016-08-30 Genentech, Inc. Enhanced protein purification through a modified protein A elution
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
WO2011028952A1 (fr) 2009-09-02 2011-03-10 Xencor, Inc. Compositions et procédés pour une co-liaison bivalente et monovalente simultanée d'antigènes
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2486141B1 (fr) 2009-10-07 2018-01-10 MacroGenics, Inc. Polypeptides contenant une région fc qui présentent une fonction d'effecteur améliorée due à des modifications de l'étendue de la fucosylation, et leurs méthodes d'utilisation
PE20121531A1 (es) 2009-10-15 2012-12-22 Abbott Lab Inmunoglobulinas con dominio variable dual
MX337290B (es) * 2009-10-19 2016-02-24 Hoffmann La Roche Anticuerpos anti igg reactivos no cruzados.
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP2325185A1 (fr) 2009-10-28 2011-05-25 GPC Biotech AG Inhibiteur de Plk
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011097527A2 (fr) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection de fractions thérapeutiques avec des régions fc améliorées
US20120309056A1 (en) 2010-02-04 2012-12-06 Leon Arnaud Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
US9175086B2 (en) * 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
AU2011222012C1 (en) 2010-03-02 2015-02-26 Kyowa Kirin Co., Ltd. Modified antibody composition
MA34062B1 (fr) 2010-03-04 2013-03-05 Macrogenics Inc Anticorps réagissant avec b7-h3, fragments immunologiquement actifs associés et utilisations associées
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR20180000342A (ko) 2010-03-22 2018-01-02 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
EP2554669B1 (fr) 2010-03-26 2018-09-19 Kyowa Hakko Kirin Co., Ltd. Nouvel anticorps ayant un site de modification introduit dans celui-ci, et fragment d'anticorps
US9169328B2 (en) 2010-03-26 2015-10-27 Memorial Sloan Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
EP2552957A4 (fr) 2010-03-29 2013-11-20 Zymeworks Inc Anticorps présentant une fonction effectrice améliorée ou supprimée
ES2993140T3 (en) 2010-04-02 2024-12-23 Amunix Pharmaceuticals Inc Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011130332A1 (fr) 2010-04-12 2011-10-20 Academia Sinica Puces au glycane pour la recherche par criblage haut débit de virus
EP2563391B1 (fr) 2010-04-27 2020-08-26 Roche Glycart AG Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
EP2975409B1 (fr) 2010-05-10 2018-10-31 Academia Sinica Congénères d'oseltamivir ayant une activité anti-grippale et de détermination de la susceptibilité d'oseltamivir des virus de la grippe
KR101848225B1 (ko) 2010-05-14 2018-04-12 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
SG10201804385YA (en) 2010-05-17 2018-06-28 Emd Millipore Corp Stimulus responsive polymers for the purification of biomolecules
SG10201710439UA (en) 2010-05-25 2018-01-30 Genentech Inc Methods of purifying polypeptides
WO2011150241A2 (fr) 2010-05-28 2011-12-01 Genentech, Inc. Réduction du niveau de lactate et augmentation de la production de polypeptides par régulation négative de l'expression de la lactate déshydrogénase et de la pyruvate déshydrogénase kinase
KR102058307B1 (ko) 2010-06-24 2019-12-20 제넨테크, 인크. 단백질-함유 제제를 안정화시키기 위한 알킬글리코시드 함유 조성물 및 방법
WO2012006500A2 (fr) 2010-07-08 2012-01-12 Abbott Laboratories Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN103180439A (zh) 2010-07-09 2013-06-26 比奥根艾迪克依蒙菲利亚公司 嵌合凝血因子
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
EP2601216B1 (fr) 2010-08-02 2018-01-03 MacroGenics, Inc. Di-anticorps covalents et utilisations associées
JPWO2012017925A1 (ja) 2010-08-02 2013-10-03 協和発酵キリン株式会社 物質の製造方法
CN103153341B (zh) 2010-08-03 2015-05-27 霍夫曼-拉罗奇有限公司 慢性淋巴细胞性白血病(cll)生物标志物
JP2013537415A (ja) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
EP2600901B1 (fr) 2010-08-06 2019-03-27 ModernaTX, Inc. Compositions pharmaceutiques a base d'acides nucléiques modifiés et leur utilisation medicale
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
CA2806851C (fr) * 2010-08-17 2019-12-03 F. Hoffmann-La Roche Ag Anticorps anti-igg1 humaine
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
PH12013500337A1 (en) 2010-08-26 2017-08-23 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
WO2012030512A1 (fr) 2010-09-03 2012-03-08 Percivia Llc. Procédé de purification de protéine en flux
BR112013007862A2 (pt) 2010-10-01 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos manipulados e métodos de uso dos mesmos.
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
ES2661981T3 (es) 2010-12-15 2018-04-04 Inter-University Research Institute Corporation Research Organization Of Information And Systems Procedimiento de producción de una proteína
CN103261229A (zh) 2010-12-16 2013-08-21 罗切格利卡特公司 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
EP2651979B1 (fr) 2010-12-17 2019-08-28 Neurimmune Holding AG Anticorps anti-sod1 humains
TW201249865A (en) 2010-12-21 2012-12-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012091023A1 (fr) 2010-12-27 2012-07-05 協和発酵キリン株式会社 Procédé d'élaboration d'une solution aqueuse contenant un milieu de culture et un agent chélatant
WO2012095514A1 (fr) 2011-01-14 2012-07-19 Vivalis Système de production de protéines recombinantes
US9433686B2 (en) 2011-01-31 2016-09-06 The Regents Of The University Of California Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function
WO2012118750A2 (fr) 2011-02-28 2012-09-07 Genentech, Inc. Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
DK2691417T4 (en) 2011-03-29 2025-01-02 Roche Glycart Ag Antistof fc-varianter
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
EP2506015A1 (fr) 2011-04-01 2012-10-03 Universität Regensburg Signature pronostique et thérapeutique pour le mélanome malin
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
EP2707723B1 (fr) 2011-05-12 2016-02-10 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
NZ618016A (en) 2011-05-21 2015-05-29 Macrogenics Inc Deimmunized serum-binding domains and their use for extending serum half-life
SMT201900239T1 (it) 2011-05-21 2019-05-10 Macrogenics Inc Molecole di legame a cd3 in grado di legare cd3 umano e non umano
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
WO2012177972A1 (fr) 2011-06-23 2012-12-27 Biogen Idec International Neuroscience Gmbh Molécules de liaison anti-alpha-synucléine
EP2537933A1 (fr) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
CA2839513A1 (fr) 2011-07-06 2013-01-10 Morphosys Ag Associations therapeutiques d'anticorps anti - cd20 et anti - gm - csf et leurs utilisations
KR20140004231A (ko) 2011-07-08 2014-01-10 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
WO2019071023A1 (fr) 2017-10-04 2019-04-11 Yale University Compositions et procédés de fabrication de polypeptides contenant de la sélénocystéine
WO2013009868A1 (fr) 2011-07-11 2013-01-17 Yale University Compositions et procédés de fabrication de polypeptides contenant de la sélénocystéine
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
EP2550975A1 (fr) 2011-07-29 2013-01-30 Sanofi Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab
EP2551348B1 (fr) 2011-07-29 2014-09-24 Icon Genetics GmbH Production de N-glycanes galactosylatées dans des plantes
WO2013022855A1 (fr) 2011-08-05 2013-02-14 Xencor, Inc. Anticorps avec points isoélectriques modifiés et immunofiltration
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013049362A2 (fr) 2011-09-27 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Méthode de traitement de la sclérose en plaques par la déplétion intrathécale de lymphocytes b et biomarqueurs pour choisir des patients atteints d'une sclérose en plaques progressive
KR102014061B1 (ko) 2011-10-03 2019-08-28 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
AU2012320847B2 (en) 2011-10-04 2018-03-08 Icon Genetics Gmbh Nicotiana benthamiana plants deficient in fucosyltransferase activity
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
SG11201401791WA (en) 2011-10-24 2014-08-28 Abbvie Inc Immunobinders directed against sclerostin
BR112014010008A2 (pt) 2011-10-26 2018-09-04 Novartis Ag anticorpos monoclonais, seus usos e ácidos nucleicos
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
RS63244B1 (sr) 2011-12-16 2022-06-30 Modernatx Inc Kompozicije modifikovane mrna
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
CN104334196B (zh) 2012-02-16 2018-04-10 Atyr 医药公司 用于治疗自身免疫疾病和炎性疾病的组氨酰‑tRNA合成酶
WO2013148249A1 (fr) 2012-03-27 2013-10-03 Genentech, Inc. Opérations de récolte améliorées pour protéines recombinées
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9192651B2 (en) 2012-04-02 2015-11-24 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
EP2863940A4 (fr) 2012-06-08 2016-08-10 Biogen Ma Inc Facteurs de coagulation chimériques
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
SI3495387T1 (sl) 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
CA2880701A1 (fr) 2012-08-18 2014-02-27 Academia Sinica Sondes permeables aux cellules pour l'identification et l'imagerie de sialidases
US9547009B2 (en) 2012-08-21 2017-01-17 Academia Sinica Benzocyclooctyne compounds and uses thereof
EP4074728A1 (fr) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Peptides modifiés comprenant un groupe azido
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014052713A2 (fr) 2012-09-27 2014-04-03 Massachusetts Institute Of Technology Protéines de liaison à her2 et vegf-a à stabilité améliorée
EP2903610B1 (fr) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Traitements antinéoplasiques
US20150238602A1 (en) 2012-10-09 2015-08-27 Biogen Idec Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
TR201910662T4 (tr) 2012-10-12 2019-08-21 Medimmune Ltd Pirrolobenzodiazepinler ve bunlara ait konjugatlar.
TW201838651A (zh) 2012-11-01 2018-11-01 美商艾伯維有限公司 穩定雙重可變區域免疫球蛋白蛋白質調配物
MX2015005593A (es) 2012-11-01 2016-02-05 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas.
JP6437441B2 (ja) 2012-11-02 2018-12-12 ティージー セラピューティクス インコーポレイテッド 抗ｃｄ２０抗体およびｐｉ３キナーゼ選択的阻害剤の組み合わせ
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP2934602B1 (fr) 2012-12-19 2019-02-27 Genentech, Inc. Procédés et compositions pour le marquage de protéines par un radiohalogène
CA2896066C (fr) 2012-12-21 2022-07-12 Biogen Ma Inc. Anticorps anti-tau humains
CA2896824A1 (fr) 2012-12-31 2014-07-03 Neurimmune Holding Ag Anticorps humains recombinants destines a la therapie et a la prevention de maladies associees aux polyomavirus
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10309969B2 (en) * 2013-01-24 2019-06-04 Abtlas Co., Ltd. Protein combination-based FV library, and preparation method therefor
WO2014124227A1 (fr) 2013-02-07 2014-08-14 Immunomedics, Inc. Forme de pro-médicament (p2pdox) de la 2-pyrrolinodoxorubicine fortement puissante conjuguée à des anticorps pour la thérapie ciblée du cancer
FI3889173T3 (fi) 2013-02-15 2023-10-02 Bioverativ Therapeutics Inc Optimoitu tekijä viii:n geeni
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
RU2019120404A (ru) 2013-03-13 2019-08-06 Дженентек, Инк. Составы антител
AU2014244286B2 (en) 2013-03-14 2018-11-08 Duke University Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
CA2904528C (fr) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Variants de fc
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
TWI745671B (zh) 2013-03-15 2021-11-11 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
BR112015025347A2 (pt) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetil-nafto [2-3-b] furan-4,9-diona para uso no tratamento do câncer
HUE058364T2 (hu) 2013-04-19 2022-07-28 Cytune Pharma Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
EP2805730A1 (fr) 2013-05-21 2014-11-26 Bergen Teknologioverforing AS Donneurs d'oxyde nitrique pour le traitement du syndrome de fatigue chronique
WO2014190441A1 (fr) 2013-05-31 2014-12-04 Zymeworks Inc. Hétéromultimères à fonction effectrice réduite ou silencieuse
EP3013365B1 (fr) 2013-06-26 2019-06-05 Academia Sinica Antigènes rm2 et leur utilisation
EP3013347B1 (fr) 2013-06-27 2019-12-11 Academia Sinica Conjugués de glycane et leur utilisation
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2839842A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
EP2840091A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
WO2015035044A2 (fr) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Variants fc présentant une cytotoxicité cellulaire dépendante des anticorps améliorée
EP3041484B1 (fr) 2013-09-06 2021-03-03 Academia Sinica Activation des cellules humaines inkt à l'aide de glycolipides ayant des groupes glycolsyles modifiés
IL312865B1 (en) 2013-09-11 2025-02-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-reducing agents
EP3052106A4 (fr) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
CA2926218A1 (fr) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides codant pour un recepteur de lipoproteines de faible densite
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
US20160256460A1 (en) 2013-11-01 2016-09-08 Bergen Teknologioverføring As Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
CA2963178C (fr) 2013-11-12 2023-01-24 Ogd2 Pharma Anticorps derive d'une igg1 humaine ayant une activite pro-apoptique
EP3083690A1 (fr) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Méthodes de traitement du cancer à l'aide d'antagonistes se liant à l'axe pd-1 et d'anticorps anti-cd20
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
WO2015130416A1 (fr) 2014-02-25 2015-09-03 Immunomedics, Inc. Anticorps rfb4 humanisés anti-cd22
EP2915569A1 (fr) 2014-03-03 2015-09-09 Cytune Pharma Procédé de purification de conjugués à base Il -15/IL-15Ralpha
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EP3129767B1 (fr) 2014-03-27 2021-09-01 Academia Sinica Composés de marquage réactifs et leurs utilisations
ES2775431T3 (es) 2014-03-28 2020-07-27 Xencor Inc Anticuerpos biespecíficos que se unen a CD38 y CD3
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
EP3134113A4 (fr) 2014-04-25 2017-11-29 University of Florida Research Foundation, Inc. Méthodes permettant qu'un sujet reçoive des doses multiples de virus adéno-associé recombinant
KR102512592B1 (ko) 2014-05-27 2023-03-21 아카데미아 시니카 항-ｈｅｒ2 글리코항체 및 이의 용도
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
KR102494193B1 (ko) 2014-05-28 2023-01-31 아카데미아 시니카 항-ｔｎｆ-알파 글리코항체 및 이의 용도
WO2015191969A1 (fr) 2014-06-13 2015-12-17 Mayo Foundation For Medical Education And Research Traitement de lymphomes
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
EP3160478A4 (fr) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Gène du facteur ix optimisé
PL3166401T3 (pl) 2014-07-09 2021-01-25 F. Hoffmann-La Roche Ag Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu
EP4406549A3 (fr) 2014-07-29 2025-01-08 Neurimmune Holding AG Anticorps anti-huntingtine (htt) humains et leurs utilisations
EP3191500A4 (fr) 2014-09-08 2018-04-11 Academia Sinica Activation des cellules inkt humaines par des glycolipides
CN106687481B (zh) 2014-09-10 2022-03-22 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
SG11201701821QA (en) 2014-09-15 2017-04-27 Genentech Inc Antibody formulations
US20160082120A1 (en) 2014-09-23 2016-03-24 Genentech, Inc. METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015326911B2 (en) 2014-09-30 2021-07-08 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
MX2017004306A (es) 2014-10-01 2017-12-20 Eagle Biologics Inc Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad.
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
SMT202000438T1 (it) 2014-11-17 2020-09-10 Regeneron Pharma Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20
MA55043A (fr) 2014-11-26 2021-12-29 Xencor Inc Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20
WO2016086196A2 (fr) 2014-11-26 2016-06-02 Xencor, Inc. Anticorps hétérodimériques se liant aux antigènes cd3 et cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016105450A2 (fr) 2014-12-22 2016-06-30 Xencor, Inc. Anticorps trispécifiques
EP3242893A1 (fr) 2015-01-08 2017-11-15 Biogen MA Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI736523B (zh) 2015-01-24 2021-08-21 中央研究院 新穎聚醣結合物及其使用方法
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2016149485A1 (fr) 2015-03-17 2016-09-22 The Regents Of The University Of California Nouvelle chimio-immunothérapie pour cancer épithélial
CN115368460A (zh) 2015-03-17 2022-11-22 纪念斯隆-凯特林癌症中心 抗muc16抗体及其应用
EP4450524A2 (fr) 2015-05-11 2024-10-23 F. Hoffmann-La Roche AG Compositions et méthodes de traitement de la néphropathie lupique
SMT202000226T1 (it) 2015-05-30 2020-05-08 Molecular Templates Inc Impalcatura di subunita' a della tossina shiga de-immunizzate e molecole di targeting cellulare comprendenti la stessa
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
BR112017024610A2 (pt) 2015-06-24 2018-07-31 F. Hoffmann-La Roche Ag anticorpos para receptor antitransferrina com afinidade especificada
EP3108897A1 (fr) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Anticorps contre le csf-1r humain permettant d'induire une lymphocytose dans les lymphomes ou les leucémies
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
CN108472337B (zh) 2015-08-03 2022-11-25 比奥贝拉蒂治疗公司 因子ix融合蛋白以及其制备和使用方法
PT3334747T (pt) 2015-08-13 2023-12-12 Amgen Inc Formulação de gonadotrofina líquida estável
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
US11713358B2 (en) 2015-08-28 2023-08-01 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
US11352426B2 (en) 2015-09-21 2022-06-07 Aptevo Research And Development Llc CD3 binding polypeptides
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN108473555B (zh) 2015-11-02 2022-10-25 生物蛋白有限公司 条件活性多肽
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
KR20180098625A (ko) 2015-12-30 2018-09-04 제넨테크, 인크. 분해가 감소된 폴리소르베이트를 갖는 제형
EP3399861A4 (fr) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Procédés de traitement du cancer par interféron
HRP20221089T1 (hr) 2016-02-01 2022-11-25 Bioverativ Therapeutics Inc. Optimizirani geni faktora viii
AU2017217881B2 (en) 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CN108699155B (zh) 2016-03-01 2023-03-21 豪夫迈·罗氏有限公司 具有改变的细胞死亡诱导的奥滨尤妥珠单抗变体
WO2017149018A1 (fr) 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits de prédiction du risque de rechute chez des patients souffrant d'un syndrome néphrotique idiopathique
CN109195996A (zh) 2016-03-08 2019-01-11 中央研究院 N-聚醣及其阵列的模组化合成方法
UA125378C2 (uk) 2016-03-14 2022-03-02 Універшітетет І Осло МОДИФІКОВАНІ ІМУНОГЛОБУЛІНИ ЗІ ЗМІНЕНИМ ЗВ'ЯЗУВАННЯМ FcRn
JP7034489B2 (ja) 2016-03-15 2022-03-14 アイタブメッド （エイチケイ） リミテッド 多重特異性Ｆａｂ融合タンパクおよびその使用
WO2017165440A1 (fr) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Procédés de réduction de la toxicité d'un médicament chimiothérapeutique
WO2017165439A1 (fr) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique
CA3019373A1 (fr) 2016-03-29 2017-10-05 Geltor, Inc. Expression de proteines dans des bacteries gram negatif, avec un rapport du volume periplasmique au volume cytoplasmique compris entre 0,5:1 et 10:1
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
US10961311B2 (en) 2016-04-15 2021-03-30 Macrogenics, Inc. B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof
WO2017182608A1 (fr) 2016-04-22 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions vaccinales pour le traitement des malignités des cellules b
EA201892284A1 (ru) 2016-05-27 2019-08-30 Тг Терапьютикс, Инк. Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific antibodies inhibit immunological checkpoint
WO2017218698A1 (fr) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Anticorps à domaines ch2 modifiés, compositions les contenant et leurs procédés d'utilisation
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3030745A1 (fr) 2016-07-13 2018-01-18 Biogen Ma Inc. Schemas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de demyelinisation
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
JP7213549B2 (ja) 2016-08-22 2023-01-27 シーエイチオー ファーマ インコーポレイテッド 抗体、結合性断片、および使用の方法
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN107384932B (zh) 2016-08-31 2020-10-20 北京天广实生物技术股份有限公司 抗人cd20人源化单克隆抗体mil62、其制备方法及用途
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3506942B1 (fr) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Compositions d'agents de liaison et de porteuses pd-l1 pour le traitement de cancers
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3035655A1 (fr) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Procedes de traitement du cancer exprimant pd-l1
WO2018048958A1 (fr) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Compositions d'agents de liaison, de paclitaxel et d'albumine et leurs procédés d'utilisation et de production
EP3509634A1 (fr) 2016-09-09 2019-07-17 TG Therapeutics Inc. Combinaison d'un anticorps anti-cd20, d'un inhibiteur de pi3 kinase-delta et d'un anticorps anti-pd-1 ou anti-pd-l1 pour le traitement de cancers hématologiques
CN108421048B (zh) * 2016-09-28 2021-04-20 首都医科大学附属北京世纪坛医院 纳米活性碳靶向药物递送系统、制备方法及其用途
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
WO2018098376A1 (fr) 2016-11-22 2018-05-31 Elektrofi, Inc. Particules comprenant un agent thérapeutique ou diagnostique et des suspensions et leurs procédés d'utilisation
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018100096A1 (fr) 2016-12-01 2018-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Utilisation de la concentration plasmatique d'igg anti-uchl1 pour diagnostiquer le syndrome néphrotique idiopathique sensible aux stéroïdes
JP2020500874A (ja) 2016-12-02 2020-01-16 バイオベラティブ セラピューティクス インコーポレイテッド キメラ凝固因子を使用して血友病性関節症を処置する方法
CN110520149A (zh) 2016-12-02 2019-11-29 比奥维拉迪维治疗股份有限公司 诱导对凝血因子的免疫耐受性的方法
US20210238259A1 (en) 2017-01-31 2021-08-05 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
SG11202003754YA (en) 2017-05-16 2020-05-28 Bhamis Research Laboratory Pvt Ltd High concentration protein formulations with reduced viscosity
WO2018213424A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Méthodes pour le traitement du cancer
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
WO2019011918A1 (fr) 2017-07-10 2019-01-17 International - Drug - Development - Biotech Traitement de malignités de lymphocytes b à l'aide d'anticorps anti-cd19 pro-apoptotiques afucosylés en combinaison avec des anticorps anti-cd20 ou des agents chimiothérapeutiques
WO2019020606A1 (fr) 2017-07-26 2019-01-31 F. Hoffmann-La Roche Ag Polythérapie avec un inhibiteur bet, un inhibiteur bcl-2 et un anticorps anti-cd20
US12168776B2 (en) 2017-08-09 2024-12-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
WO2019077123A1 (fr) 2017-10-20 2019-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et kits pour identifier si un sujet est atteint ou risque d'être atteint d'une myopathie auto-immune
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CA3082383A1 (fr) 2017-11-08 2019-05-16 Xencor, Inc. Anticorps bispecifiques et monospecifiques utilisant de nouvelles sequences anti-pd-1
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
WO2019195623A2 (fr) 2018-04-04 2019-10-10 Xencor, Inc. Anticorps hétérodimères qui se lient à la protéine d'activation des fibroblastes
WO2019204665A1 (fr) 2018-04-18 2019-10-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant pd-1 contenant des protéines de fusion fc d'il-15/il-15ra, domaines de liaison à l'antigène pd-1 et utilisations associées
GB2611498B (en) 2018-04-18 2023-07-19 Ucl Business Ltd Composition comprising an engineered regulatory T cell (Treg)
EP3781598A1 (fr) 2018-04-18 2021-02-24 Xencor, Inc. Protéines de fusion hétérodimères ciblant tim-3 contenant des protéines de fusion fc d'il-15/il-15ra et domaines de liaison à l'antigène de tim-3
WO2019210054A1 (fr) 2018-04-27 2019-10-31 Biogen Ma Inc. Anticorps anti-(poly-ga) dirigé contre des répétitions dipeptidiques (dpr) d'origine humaine
KR20210016562A (ko) 2018-05-23 2021-02-16 에이디씨 테라퓨틱스 에스에이 분자 애쥬번트
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
CA3105947A1 (fr) 2018-07-09 2020-01-16 Millennium Pharmaceuticals, Inc. Administration d'inhibiteur d'enzyme d'activation sumo et anticorps anti-cd20
WO2020028909A1 (fr) 2018-08-03 2020-02-06 Brown University Formulations orales présentant une absorption accrue
CN109273050B (zh) * 2018-08-03 2021-07-13 五邑大学 一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
US11590223B2 (en) 2018-08-31 2023-02-28 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
CN112955172A (zh) 2018-09-17 2021-06-11 美国卫生和人力服务部 靶向cd19和cd20的双顺反子嵌合抗原受体及其用途
KR20210069641A (ko) 2018-10-03 2021-06-11 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
EP3864127A1 (fr) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Procédé de transfert de gaz de membrane dans une culture de bioréacteur à haute densité
EP3863672A4 (fr) 2018-10-11 2022-06-29 The Scripps Research Institute Composés d'anticorps avec arginine réactive et conjugués anticorps-médicament associés
KR102262012B1 (ko) 2018-10-15 2021-06-09 연세대학교 산학협력단 생산성이 향상된 항체 및 이의 제조방법
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
JP7453151B2 (ja) 2018-11-02 2024-03-19 協和キリン株式会社 液体培地の調製方法
CA3119467A1 (fr) 2018-11-20 2020-05-28 Cornell University Complexes macrocycliques de radionucleides et leur utilisation en radiotherapie du cancer
AU2018451747A1 (en) 2018-12-06 2021-06-17 F. Hoffmann-La Roche Ag Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody
WO2020115262A1 (fr) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de cd26 et cd39 en tant que nouveaux marqueurs phénotypiques pour évaluer la maturation de lymphocytes t ffoxp3+ et leurs utilisations à des fins de diagnostic
EP3917500A2 (fr) 2019-01-31 2021-12-08 Elektrofi, Inc. Formation et morphologie de particules
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
CN113728107B (zh) 2019-02-18 2022-06-24 Atb治疗公司 在植物细胞或整株植物中产生结合物-毒素融合蛋白的方法
BR112021016923A2 (pt) 2019-02-27 2021-11-03 Genentech Inc Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
KR20210145152A (ko) 2019-04-01 2021-12-01 제넨테크, 인크. 단백질-함유 제제들의 안정화를 위한 조성물들 및 방법들
EP3953380A4 (fr) 2019-04-12 2023-01-25 Geltor, Inc. Élastine de recombinaison et production associée
MX2021013825A (es) 2019-05-14 2022-01-18 Genentech Inc Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
CN114269749B (zh) 2019-06-10 2024-10-01 苏特罗生物制药公司 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
JP2022536800A (ja) 2019-06-17 2022-08-18 ストロ バイオファーマ インコーポレーテッド Ｔｏｌｌ様受容体（ｔｌｒ）７／８アゴニストとしての１－（４－（アミノメチル）ベンジル）－２－ブチル－２ｈ－ピラゾロ［３，４－ｃ］キノリン－４－アミン誘導体および関連化合物、ならびにがん療法および診断に使用するためのその抗体薬物コンジュゲート
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
CA3149049A1 (fr) 2019-08-30 2021-03-04 Vestlandets Innovasjonsselskap As Procede de traitement du syndrome de fatigue chronique a l'aide d'un agent inhibiteur ou cytotoxique contre des cellules plasmatiques
WO2021050645A1 (fr) 2019-09-12 2021-03-18 Genentech, Inc. Compositions et méthodes de traitement du lupus néphrétique
CN114514035A (zh) 2019-09-13 2022-05-17 伊勒卓菲公司 递送用于治疗疾病的治疗性生物制剂的组合物和方法
EP4045090A1 (fr) 2019-10-18 2022-08-24 Genentech, Inc. Procédés d'utilisation d'immunoconjugués anti-cd79b pour traiter un lymphome diffus à grandes cellules b
US20230022576A1 (en) 2019-11-19 2023-01-26 Protalix Ltd. Removal of constructs from transformed cells
IL295202A (en) 2020-01-31 2022-10-01 Seagen Inc Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
US20230065628A1 (en) 2020-02-19 2023-03-02 Elektrofi, Inc. Droplet Formation and Particle Morphology
EP4114852A1 (fr) 2020-03-03 2023-01-11 Sutro Biopharma, Inc. Anticorps comprenant des étiquettes de glutamine spécifiques à un site, leurs procédés de préparation et d'utilisation
JP2023522627A (ja) 2020-04-17 2023-05-31 エレクトロフィ，インコーポレイテッド 連続的な液滴形成及び脱水によって粒子を形成する方法
AU2021259861A1 (en) 2020-04-24 2022-11-17 Genentech, Inc. Methods of using anti-CD79b immunoconjugates
IL297545A (en) 2020-04-26 2022-12-01 Biocytogen Pharmaceuticals Beijing Co Ltd Modified immunoglobulins
WO2021223048A1 (fr) 2020-05-03 2021-11-11 上海美雅珂生物技术有限责任公司 Conjugué anticorps-médicament et sa préparation
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
GB202007842D0 (en) 2020-05-26 2020-07-08 Quell Therapeutics Ltd Polypeptide useful in adoptive cell therapy
JP2023537565A (ja) 2020-06-24 2023-09-04 バイオベラティブ セラピューティクス インコーポレイテッド タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
GB202012331D0 (en) 2020-08-07 2020-09-23 Petmedix Ltd Therapeutic antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
CN112062855B (zh) 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022043415A1 (fr) 2020-08-27 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de détection de la présence d'auto-anticorps spécifiques à un pemphigus dans un échantillon
GB202013477D0 (en) 2020-08-27 2020-10-14 Quell Therapeutics Ltd Nucleic acid constructs for expressing polypeptides in cells
KR20230066581A (ko) 2020-09-10 2023-05-16 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
WO2022053653A1 (fr) 2020-09-10 2022-03-17 Genmab A/S Anticorps bispécifiques contre cd3 et cd20 de traitement de la leucémie lymphoïde chronique
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CN116507363A (zh) 2020-09-10 2023-07-28 健玛保 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
AU2021341509A1 (en) 2020-09-10 2023-04-13 Genmab A/S Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
KR20230073270A (ko) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
WO2022074646A1 (fr) 2020-10-05 2022-04-14 Protalix Ltd. Cellules végétales inactivées de type dicer
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022103983A2 (fr) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Composés de fluorénylméthyloxycarbonyle et de fluorénylméthylaminocarbonyle, conjugués protéines associés et méthodes d'utilisation
WO2022104150A1 (fr) 2020-11-12 2022-05-19 Tg Therapeutics, Inc. Triple combinaison pour traiter des malignités des lymphocytes b
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CA3212665A1 (fr) 2021-03-09 2022-09-15 Xencor, Inc. Anticorps heterodimeriques se liant a cd3 et a cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
IL305283A (en) 2021-03-15 2023-10-01 Genentech Inc Compositions and methods of treating lupus nephritis
CN117529505A (zh) 2021-03-24 2024-02-06 美国卫生和人力服务部 设计为减少逆转录病毒重组的双顺反子嵌合抗原受体及其用途
TW202306983A (zh) 2021-04-20 2023-02-16 日商日本醫事物理股份有限公司 抗ｃｄ２０抗體之放射性複合體，及放射性醫藥
EP4334354A1 (fr) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Anticorps anti-alk et leurs procédés d'utilisation
CA3218170A1 (fr) 2021-05-12 2022-11-17 Jamie Harue HIRATA Methodes d'utilisation d'immunoconjugues anti-cd79b pour traiter un lymphome diffus a grandes cellules b
US20240270862A1 (en) 2021-06-01 2024-08-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of b cell depleting agents for the treatment of rheumatic heart disease
CN117412988A (zh) 2021-06-08 2024-01-16 修普霍斯生物科学有限公司 抗体-nkg2d配体结构域融合蛋白
BR112023025884A2 (pt) 2021-06-08 2024-02-27 Xyphos Biosciences Inc Proteína de fusão de domínio de ligante de anticorpo de nkg2d
CN117580862A (zh) 2021-06-17 2024-02-20 葛兰素史克知识产权有限公司 用于治疗长新冠和/或SARS-CoV-2感染后急性后遗症(PASC)的方法的抗BAFF抗体
JP2024526122A (ja) 2021-06-17 2024-07-17 ペットメディックス・リミテッド 抗イヌｃｄ２０抗体
EP4377338A2 (fr) 2021-07-27 2024-06-05 Novab, Inc. Anticorps anti-vlrb génétiquement modifiés présentant des fonctions effectrices immunitaires
WO2023015234A1 (fr) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Procédés de culture cellulaire pour la production de protéines thérapeutiques
WO2023012486A1 (fr) 2021-08-06 2023-02-09 Petmedix Ltd Variants de fc d'anticorps
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
IL310963A (en) 2021-08-23 2024-04-01 Bioverativ Therapeutics Inc Production of closed DNA with inverted repeat sequences
WO2023049687A1 (fr) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Procédés de régulation du taux d'oxygène dissous (do) dans une solution comprenant une protéine recombinante dans un récipient de stockage
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
TW202346327A (zh) 2021-09-30 2023-12-01 美商百歐維拉提夫治療公司 編碼具有降低免疫原性的因子ｖｉｉｉ多肽之核酸
WO2023097024A1 (fr) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Anticorps contre ctla-4 et leurs méthodes d'utilisation
US20250051472A1 (en) 2021-12-17 2025-02-13 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
CA3241407A1 (fr) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Plateforme pour decouverte d'anticorps
US20230303693A1 (en) 2022-01-28 2023-09-28 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
EP4472670A1 (fr) 2022-02-04 2024-12-11 Dana-Farber Cancer Institute, Inc. Compositions et méthodes de traitement de troubles neurologiques
WO2023152486A1 (fr) 2022-02-09 2023-08-17 Petmedix Ltd Anticorps thérapeutiques
WO2023164487A1 (fr) 2022-02-22 2023-08-31 Brown University Compositions et procédés pour obtenir une absorption systémique de particules suite à une administration par voie orale ou muqueuse
EP4508080A1 (fr) 2022-04-11 2025-02-19 Astrazeneca AB Protéines de liaison à des lymphocytes t
CN119403542A (zh) 2022-04-29 2025-02-07 伊勒卓菲公司 可注射悬浮液
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
IL316919A (en) 2022-06-27 2025-01-01 Sutro Biopharma Inc Β-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2024015229A1 (fr) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Charges utiles-lieurs clivables par une protéase/enzyme et conjugués protéiques
WO2024039670A1 (fr) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anticorps anti-cldn4 et leurs méthodes d'utilisation
WO2024039672A2 (fr) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Anticorps anti-mlsn et leurs méthodes d'utilisation
WO2024102734A1 (fr) 2022-11-08 2024-05-16 Genentech, Inc. Compositions et méthodes de traitement du syndrome néphrotique idiopathique de l'enfant
WO2024153636A1 (fr) 2023-01-17 2024-07-25 Institut National de la Santé et de la Recherche Médicale Vasorine en tant que biomarqueur et biocible en néphrologie
WO2024182516A1 (fr) 2023-02-28 2024-09-06 Juno Therapeutics, Inc. Thérapie cellulaire pour le traitement de maladies auto-immunes systémiques
WO2024254455A1 (fr) 2023-06-08 2024-12-12 Genentech, Inc. Signatures de macrophages pour méthodes diagnostiques et thérapeutiques pour un lymphome
WO2025021782A1 (fr) 2023-07-24 2025-01-30 Institut National de la Santé et de la Recherche Médicale Procédés pour déterminer si un sujet souffrant de néphrite lupique (ln) est sensible à une thérapie par induction
WO2025029832A2 (fr) 2023-07-31 2025-02-06 Sutro Biopharma, Inc. Composés agonistes de sting et conjugués

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26804A (en) * 1860-01-10 Bridle-bit
US21781A (en) * 1858-10-12 Improved method o f lighting street-lamps by electricity
US213784A (en) * 1879-04-01 Improvement in inlaying metallic scroll-ornaments in hard rubber and allied gums
US186205A (en) * 1877-01-16 Improvement in buffing-rolls for thesoles of boots andshoes
US147885A (en) * 1874-02-24 Improvement in the manufacture of halters and bridles
US9444A (en) * 1852-12-07 Hot-air furnace
US197255A (en) * 1877-11-20 Improvement in receivers and stench-traps for street-sewers
US206903A (en) * 1878-08-13 Improvement in cultivators
US95963A (en) * 1869-10-19 Improvement in fence
US163708A (en) * 1875-05-25 Improvement in harvester-rakes
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (fr) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
USRE38008E1 (en) * 1986-10-09 2003-02-25 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US6893625B1 (en) * 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5439665A (en) * 1988-07-29 1995-08-08 Immunomedics Detection and treatment of infectious and inflammatory lesions
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH06501705A (ja) * 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5648267A (en) * 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
NZ258392A (en) * 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5678180A (en) * 1995-06-07 1997-10-14 Hughes Electronics Communication system and method providing dispatch and cellular interconnect communications
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Also Published As

Publication number Publication date
HU9501410D0 (en) 1995-06-28
SG45294A1 (en) 1998-01-16
ATE421335T1 (de) 2009-02-15
CN101007850B (zh) 2012-05-30
FR04C0018I2 (fr) 2009-11-20
TW376320B (en) 1999-12-11
CN101007851B (zh) 2012-09-12
DK2000149T3 (da) 2009-08-03
HK1109634A1 (en) 2008-06-13
GEPI20105119B (en) 2010-11-25
DE69334259D1 (de) 2009-03-12
NL300424I1 (nl) 2010-01-04
ES2321567T3 (es) 2009-06-08
ZA938466B (en) 1994-06-20
CN1270774C (zh) 2006-08-23
CN101007851A (zh) 2007-08-01
GEP20074162B (en) 2007-07-10
CN1912111B (zh) 2010-05-26
KR100365632B1 (ko) 2003-08-02
GEP20105119B (en) 2010-11-25
BR1100622A (pt) 2000-04-18
HK1109633A1 (en) 2008-06-13
HU219264B (en) 2001-03-28
CN101007850A (zh) 2007-08-01
EP2000149A1 (fr) 2008-12-10
DE69334285D1 (de) 2009-06-25
CN1912111A (zh) 2007-02-14
DK1005870T3 (da) 2009-05-18
US5736137A (en) 1998-04-07
ATE431158T1 (de) 2009-05-15
CN1607006A (zh) 2005-04-20
FR04C0018I1 (fr) 2008-09-26
IL107591A0 (en) 1994-02-27
PT1005870E (pt) 2009-04-28
EP2000149B1 (fr) 2009-05-13
ES2326144T3 (es) 2009-10-01
CN1607006B (zh) 2012-09-19
PL175557B1 (pl) 1999-01-29
MY111196A (en) 1999-09-30
US20030082172A1 (en) 2003-05-01
HUT72914A (en) 1996-06-28
HK1125574A1 (en) 2009-08-14
UA27946C2 (uk) 2000-10-16
PT2000149E (pt) 2009-07-14
IL107591A (en) 2000-02-17
CN1094965A (zh) 1994-11-16
DE122009000070I1 (de) 2010-02-11
CA2626445A1 (fr) 1994-05-26

Similar Documents

Publication Publication Date Title
LU91620I2 (fr) Rituximab et ses dérivés pharmaceutiquement acceptables - MABTHERA®
LU91089I2 (fr) Ibritumomab.